STEAP1 CAR for metastatic prostate cancer

Business opportunity Scientists at Oslo University Hospital (Norway) have developed a new chimeric antigen receptor (CAR) targeting STEAP1 positive cells. STEAP1 is expressed in about 90% of prostate cancers, and subgroups of other malignancies, and it is an...

CAR T-cell Therapy for Osteosarcoma (OSCAR)

Business opportunity The present technology has the potential to effectively treat children and adults with metastatic osteosarcoma (bone cancer) where the disease has progressed beyond the first and second line treatment. Inven2 seeks collaboration with industrial...